Anti-PIK3CA monoclonal antibody
Pre-made anti-PIK3CA monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to PIK3CA/PIK3CA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T80276-Ab-1/ GM-Tg-hg-T80276-Ab-2 | Anti-Human PIK3CA monoclonal antibody | Human |
GM-Tg-rg-T80276-Ab-1/ GM-Tg-rg-T80276-Ab-2 | Anti-Rat PIK3CA monoclonal antibody | Rat |
GM-Tg-mg-T80276-Ab-1/ GM-Tg-mg-T80276-Ab-2 | Anti-Mouse PIK3CA monoclonal antibody | Mouse |
GM-Tg-cynog-T80276-Ab-1/ GM-Tg-cynog-T80276-Ab-2 | Anti-Cynomolgus/ Rhesus macaque PIK3CA monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T80276-Ab-1/ GM-Tg-felg-T80276-Ab-2 | Anti-Feline PIK3CA monoclonal antibody | Feline |
GM-Tg-cang-T80276-Ab-1/ GM-Tg-cang-T80276-Ab-2 | Anti-Canine PIK3CA monoclonal antibody | Canine |
GM-Tg-bovg-T80276-Ab-1/ GM-Tg-bovg-T80276-Ab-2 | Anti-Bovine PIK3CA monoclonal antibody | Bovine |
GM-Tg-equg-T80276-Ab-1/ GM-Tg-equg-T80276-Ab-2 | Anti-Equine PIK3CA monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T80276-Ab-1/ GM-Tg-hg-T80276-Ab-2; GM-Tg-rg-T80276-Ab-1/ GM-Tg-rg-T80276-Ab-2; GM-Tg-mg-T80276-Ab-1/ GM-Tg-mg-T80276-Ab-2; GM-Tg-cynog-T80276-Ab-1/ GM-Tg-cynog-T80276-Ab-2; GM-Tg-felg-T80276-Ab-1/ GM-Tg-felg-T80276-Ab-2; GM-Tg-cang-T80276-Ab-1/ GM-Tg-cang-T80276-Ab-2; GM-Tg-bovg-T80276-Ab-1/ GM-Tg-bovg-T80276-Ab-2; GM-Tg-equg-T80276-Ab-1/ GM-Tg-equg-T80276-Ab-2 |
Products Name | Anti-PIK3CA monoclonal antibody |
Format | mab |
Target Name | PIK3CA |
Protein Sub-location | Introcelluar Protein |
Category of antibody | Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-PIK3CA monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-T80276-Ag-1 | Recombinant multi-species PK3CA/ PIK3CA/ CLAPO protein |
Target information
Target ID | GM-T80276 |
Target Name | PIK3CA |
Gene ID | 5290,18706,170911,709959,488084,101097413,282306,100058141 |
Gene Symbol and Synonyms | 6330412C24Rik,caPI3K,CCM4,CLAPO,CLOVE,CWS5,MCAP,MCM,MCMTC,p110,p110-alpha,p110alpha,PI3K,PI3K-alpha,PIK3CA |
Uniprot Accession | P42336,A0A0G2K344,P32871 |
Uniprot Entry Name | PK3CA_HUMAN,PK3CA_RAT,PK3CA_BOVIN |
Protein Sub-location | Introcelluar Protein |
Category | Therapeutics Target |
Disease | Non-Small Cell Lung Cancer |
Gene Ensembl | ENSG00000121879 |
Target Classification | Kinase |
The target: PIK3CA, gene name: PIK3CA, also named as CLAPO, CLOVE, CWS5, MCAP, MCM, MCMTC, PI3K, PI3K-alpha, p110-alpha. Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. A pseudogene of this gene has been defined on chromosome 22. [provided by RefSeq, Apr 2016].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.